Morphosys to take on CAR-Ts in NHL with promising antibody

Morphosys to take on CAR-Ts in NHL with promising antibody

Source: 
Pharmaforum
snippet: 

Germany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a common form of non-Hodgkin lymphoma, saying that the phase 2 trial data is compelling enough to file with regulators later this year.